Karyopharm Therapeutics Inc.: chief accounting officer Kristin Abate sold 4,788 shares

What happened Kristin Abate, chief accounting officer, sold 4,788 shares of Karyopharm Therapeutics Inc. on Oct 16, 2026, at $0.34 per share, for $1,647 in total.

Key details

• Transaction date and price: Oct 16, 2026, sale at $0.34 per share (code S).
• Total shares sold and value: 4,788 shares for $1,647.
• Filing date: Oct 19, 2026.
• Shares owned after the transaction: not reported in the filing.
• Footnote F1: the transaction was effected pursuant to a durable automatic sale instruction plan adopted May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units; the sale does not represent a discretionary trade by the reporting person.

Why it may matter The filing shows this was a broker-assisted sale to satisfy tax withholding tied to vested restricted stock units under a pre-existing automatic sale instruction plan. A filing does not show why the insider traded or why the company acted.